Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00005892

Enrollment

Unknown

Registered

2000-06-05

Start date

2000-03-31

Completion date

Unknown

Last updated

2005-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fanconi's Anemia, Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute, Myelodysplastic Syndromes

Keywords

Fanconi's anemia, acute leukemia, acute lymphocytic leukemia, acute myeloid leukemia, acute undifferentiated leukemia, adult acute lymphoblastic leukemia, adult acute lymphoblastic leukemia in remission, adult acute myeloid leukemia, adult acute myeloid leukemia in remission, aplastic anemia, childhood acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia in remission, childhood acute myeloid leukemia, childhood acute myeloid leukemia in remission, de novo myelodysplastic syndrome, hematologic disorders, hematopoietic/lymphoid cancer, leukemia, myelodysplastic syndrome, oncologic disorders, previously treated myelodysplastic syndrome, rare disease, secondary myelodysplastic syndrome

Brief summary

OBJECTIVES: I. Determine the effectiveness of moderate dose cyclophosphamide and radiotherapy in terms of improving survival and reducing the morbidity following allogeneic bone marrow transplantation in patients with myelodysplastic syndrome and acute leukemia related to Fanconi's anemia.

Detailed description

PROTOCOL OUTLINE: Patients receive cyclophosphamide IV over 1-2 hours on day -6 through -3 and total body radiotherapy on day -1. Patients undergo allogeneic bone marrow transplantation on day 0.

Interventions

DRUGcyclophosphamide

PROCEDUREAllogeneic Bone Marrow Transplantation

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

0 Years to 54 Years

Healthy volunteers

Inclusion criteria

* Diagnosis of Fanconi's anemia with the family history and typical phenotype including: Short stature Hypoplastic radii Skin pigmentation Renal anomalies Chromosomal fragility * Evidence of Fanconi's myelodysplastic syndrome Bone marrow dysplasia of all 3 marrow cell lines AND Clonal cytogenetic abnormalities demonstrable in marrow cells * First complete remission following therapy for Fanconi's acute leukemia allowed * Must have related histocompatible donor No evidence of excessive in vitro chromosome fragility typical of Fanconi's anemia Normal CBC and bone marrow

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026